R-CDOP+intrathecal MTX

Phase 2Small molecule

FFudan University

R-CDOP+intrathecal MTX is one of 9 small molecule programs targeting Methotrexate. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MethotrexateRecruiting

MethotrexatePhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Methotrexate

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

48 2

Xeljanz

PPrism Pharmaceuticals

Approved

3 3

Jaypirca

Eli Lilly

Phase 2

1 4

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

2 5

Bavencio

EMD Serono

Phase 2

1 6

Neoral

Novartis

Phase 1

1 7

Rifampicin

Boehringer Ingelheim

Phase 1

2 8

R-CDOP+intrathecal MTX

FFudan University

Phase 2

1 9

PRX-115

PProtalix

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Methotrexate

NCT05257018

Clinical

Trials by Indication[1]

Methotrexate1 trial

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Recruiting·FFudan University·Phase 2·NCT05257018·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for R-CDOP+intrathecal MTX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-CDOP+intrathecal MTX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-CDOP+intrathecal MTX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

R-CDOP+intrathecal MTX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Methotrexate1 trial

References

Drug Info

Quick Facts

Related News